Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: A pilot study

被引:48
作者
Tempfer, CB
Jirecek, S
Riener, EK
Zeisler, H
Denschlag, D
Hefler, L
Husslem, PW
机构
[1] Univ Freiburg, Sch Med, Dept Obstet & Gynecol, D-79106 Freiburg, Germany
[2] Univ Vienna, Sch Med, Dept Obstet & Gynecol, Vienna, Austria
关键词
preeclampsia; risk; gene; polymorphism; multigenetic model;
D O I
10.1016/j.jsgi.2003.12.002
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Carriage of thrombophilic and vasoactive polymorphic alleles has been associated with various pregnancy complications. The effect of carrying multiple polymorphisms is not known. We conducted a case-control study to determine the association between eight polymorph isms of thrombophilic and vasoactive genes and the risk of severe preeclampsia. METHODS: The following polymorphisms were analyzed by sequencing-on-chip-technology using solid-phase polymerase chain reaction on oligonucleotide microarrays: factor 5 (F5) Leiden, factor 2 (F2)prothrombin G20210A, plasminogen activator inhibitor (PAI)-1 4G/5G, nitric oxide synthase (NOS) 3 T768C, NOS 3 Glu298Asp, angiotensinogen (ACT) Met235Thr, estrogen receptor (ER) alpha Pvu II, and mineralcorticoid receptor (MLR) Ser810Leu. The study comprised 24 patients with severe preeclampsia and 24 controls from a cohort of consecutive white women treated at the Obstetrics Department of the University of Vienna Medical School. Genotypes were correlated with clinical data. RESULTS: The investigated polymorphisms did not influence the risk of severe preeclampsia independently. When separately considering the simultaneous carriage of multiple thrombophilic or vasoactive polymorphisms, neither the combined carriage of thrombophilic polymorphisms (F5 Leiden, F2 G20210A, PAI-1 4G/5G), nor the combined carriage of vasoactive polymorphisms (NOS 3 T768C, NOS 3 Glu298Asp, AGT Met235Thr) conferred an increased risk of severe preeclampsia. Cumulative genotype frequencies for at least two homozygous mutant genotypes, however, were nine of 24 (38%) and two of 24 (8%) for the study and control groups, respectively (P < .05). All of these nine women with severe preeclampsia had at least two homozygous mutant genotypes of four polymorphisms, ie, F5 Leiden, NOS 3 T768C, NOS 3 Glu298Asp, or ER alpha Pvu H. CONCLUSION: Our data fail to document an independent significant influence of the investigated polymorphisms on the risk of severe preeclampsia. In an attempt to build a multigenetic model of severe preeclampsia, the combination of F5 Leiden, NOS 3 T768C, NOS 3 Glu298Asp, and ER alpha Pvu II was the most effective combination to predict the presence of severe preeclampsia in this small series of white women. Copyright (C) 2004 by the Society for Gynecologic Investigation.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 23 条
[1]   Thrombophilias and recurrent miscarriage [J].
Adelberg, AM ;
Kuller, JA .
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2002, 57 (10) :703-709
[2]  
*AM COLL OBST GYN, 2002, DIAGN MAN PREECL ECL
[3]   Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations [J].
Baudin, B .
PHARMACOGENOMICS, 2002, 3 (01) :65-73
[4]   Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome [J].
Benedetto, C ;
Marozio, L ;
Salton, L ;
Maulà, V ;
Chieppa, G ;
Massobrio, M .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (12) :1095-1100
[5]   PREGNANCY IN SISTERS AND DAUGHTERS OF ECLAMPTIC WOMEN [J].
CHESLEY, LC ;
ANNITTO, JE ;
COSGROVE, RA .
PATHOLOGIA ET MICROBIOLOGIA, 1961, 24 (04) :662-&
[6]   Familial risk of preeclampsia in Newfoundland: A population-based study [J].
Dawson, LM ;
Parfrey, PS ;
Hefferton, D ;
Dicks, EL ;
Cooper, MJ ;
Young, D ;
Marsden, PA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (07) :1901-1906
[7]   Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis [J].
Endler, G ;
Mannhalter, C .
CLINICA CHIMICA ACTA, 2003, 330 (1-2) :31-55
[8]   Paternal and maternal components of the predisposition to preeclampsia. [J].
Esplin, MS ;
Fausett, MB ;
Fraser, A ;
Kerber, R ;
Mineau, G ;
Carrillo, J ;
Varner, MW .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :867-872
[9]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[10]   A mineralocorticoid receptor mutation causing human hypertension [J].
Geller, DS .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (05) :661-665